X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical …,

“I am encouraged by the preliminary safety and efficacy data from the ongoing combination trial of ibrutinib and mavorixafor in this difficult-to-treat patient …, “I am encouraged by the preliminary safety and efficacy data from the ongoing combination trial of ibrutinib and mavorixafor in this difficult-to-treat patient …, Read More

Scroll to Top